Celldex Therapeutics, Inc. - CLDX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Kynam Capital Management, LP | 6.78% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Kynam Capital Management GP, LLC | 6.78% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Yue Tang | 6.78% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G | T. Rowe Price Associates, Inc. | 6.0% | 4,686,187 | View |
| May 15, 2026 | SCHEDULE 13G/A | Kynam Capital Management, LP | 8.77% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | Kynam Capital Management GP, LLC | 8.77% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | Yue Tang | 8.77% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | Bellevue Group AG | 1.5% | 1,200,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Bellevue Asset Management AG | 1.5% | 1,200,000 | View |
| May 06, 2026 | SCHEDULE 13G/A | FMR LLC | 5.6% | 3,749,048 | View |
| May 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 5.6% | 3,749,048 | View |
| Apr 29, 2026 | SCHEDULE 13G | Vanguard Capital Management | 5.17% | 3,446,795 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.